Photodynamic therapy

Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China

mycolabadmin

Mycetoma and chromoblastomycosis are serious fungal infections that primarily affect poor communities in tropical regions, causing permanent disability and limb loss. This review compares how China and Rwanda are tackling these diseases, finding that China has advanced laboratories and testing methods while Rwanda excels at reaching rural communities. The study recommends that both countries work together, combining China’s advanced diagnostic technology with Rwanda’s successful community health approach to better control these neglected diseases.

Fruiting body-associated Pseudomonas contact triggers ROS-mediated perylenequinone biosynthesis in Shiraia mycelium culture

mycolabadmin

Scientists discovered that bacteria living inside medicinal mushroom fruiting bodies can trigger the production of powerful healing compounds called perylenequinones through direct physical contact. These compounds are being used to fight cancer and harmful bacteria through a therapy called photodynamic therapy. The study shows that when bacteria touch the mushroom’s cells, it causes the mushroom to produce more of these therapeutic compounds by creating controlled stress that activates specific genes.

Enhancement of Perylenequinonoid Compounds Production from Strain of Pseudoshiraia conidialis by UV-Induced Mutagenesis

mycolabadmin

Researchers used UV light to mutate fungal strains that naturally produce powerful medicinal compounds called perylenequinones. These compounds show promise for treating cancer and viral infections through photodynamic therapy. Through careful mutagenesis and screening, they developed a superior fungal strain that produces over 2100 mg/L of these valuable compounds, far exceeding previous methods. The breakthrough highlights that focusing on multiple beneficial compounds rather than just one can lead to better commercial applications.

Production of fungal hypocrellin photosensitizers: Exploiting bambusicolous fungi and elicitation strategies in mycelium cultures

mycolabadmin

Hypocrellins are powerful compounds from fungi that can treat cancers and infections through light-activated therapy. Since wild sources are limited, scientists are growing these fungi in laboratory cultures and using special techniques to boost production. This review summarizes the best methods for producing hypocrellins, from choosing the right fungal strains to optimizing growing conditions and using natural stimulants to increase yields.

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation

mycolabadmin

Researchers discovered that a naturally derived compound from bamboo boosts the production of hypocrellin A, a promising cancer-fighting and antimicrobial agent made by a special fungus. By studying a key enzyme called G6PDH, they found that it acts as a molecular switch controlling hypocrellin production when the fungus senses bamboo components. This discovery enables cost-effective large-scale production of this powerful medicine through simple fermentation, potentially making novel cancer treatments and antibiotics more accessible.

Energy Metabolism Enhance Perylenequinone Biosynthesis in Shiraia sp. Slf14 through Promoting Mitochondrial ROS Accumulation

mycolabadmin

Scientists studied two similar fungi to understand how one produces more of a beneficial compound called perylenequinones (PQs), which have medical uses against infections and cancer. They discovered that the high-producing strain uses energy more efficiently, which causes tiny structures in the cells called mitochondria to produce reactive molecules (ROS). These reactive molecules trigger the fungus to make more PQs as a protective response. By controlling these processes, researchers can potentially improve the production of this valuable medicine.

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation

mycolabadmin

Researchers discovered that a specific enzyme called glucose-6-phosphate dehydrogenase (G6PDH) controls the production of hypocrellin A, a powerful therapeutic compound found in Shiraia fungi. When bamboo polysaccharides are added to fungal cultures, they trigger G6PDH activity, which then increases the production of signaling molecules that boost hypocrellin A biosynthesis. This finding could lead to better ways to produce this promising cancer-fighting photosensitizer at industrial scales using simple, cost-effective methods.

therapeutic action: Photodynamic therapy

Bridging gaps in the elimination of deep mycoses: a comparative analysis of mycetoma and chromoblastomycosis control strategies in Rwanda and China

Fruiting body-associated Pseudomonas contact triggers ROS-mediated perylenequinone biosynthesis in Shiraia mycelium culture

Enhancement of Perylenequinonoid Compounds Production from Strain of Pseudoshiraia conidialis by UV-Induced Mutagenesis

Production of fungal hypocrellin photosensitizers: Exploiting bambusicolous fungi and elicitation strategies in mycelium cultures

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation

Energy Metabolism Enhance Perylenequinone Biosynthesis in Shiraia sp. Slf14 through Promoting Mitochondrial ROS Accumulation

Glucose-6-Phosphate Dehydrogenase Modulates Shiraia Hypocrellin A Biosynthesis Through ROS/NO Signaling in Response to Bamboo Polysaccharide Elicitation